Company profile

Ticker
BMRA
Exchange
CEO
Zackary S. Irani
Employees
Incorporated in
Location
Fiscal year end
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
IRS number
952645573

BMRA stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Jan 20
9 Apr 20
31 May 20

News

Company financial data Financial data

Quarter (USD) Nov 19 Aug 19 May 19 Feb 19
Revenue 1.6M 1.19M 1.17M 1.26M
Net income -485.26K -506.3K -785.33K -678.75K
Diluted EPS -0.05 -0.05 -0.08 -0.07
Net profit margin -30.40% -42.39% -67.36% -53.82%
Operating income -489.74K -509.56K -764.82K -707.25K
Net change in cash 43.44K 120.77K -231.15K -206.98K
Cash on hand 850.99K 807.55K 686.79K 917.94K
Cost of revenue 1.13M 827.11K 985.05K 895.24K
Annual (USD) May 19 May 18 May 17 May 16
Revenue 5.2M 5.56M 5.79M 5.14M
Net income -2.39M -1.47M -908.56K -1.5M
Diluted EPS -0.26 -0.17 -0.11 -0.2
Net profit margin -46.01% -26.34% -15.69% -29.18%
Operating income -2.41M -1.48M -954.63K -826.95K
Net change in cash -518.12K -20.56K -663.46K 800.62K
Cash on hand 686.79K 1.2M 1.23M 1.89M
Cost of revenue 3.91M 3.81M 3.77M 3.62M

Financial data from Biomerica earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
1 Apr 20 Barbieri Allen Common Stock Gift Dispose G 0 23,000 0 137,289
28 Feb 20 Zackary S. Irani Common Stock Other Aquire J 2.85 78,431 223.53K 1,002,160
2 Jan 20 Janet Moore Common Stock Gift Dispose G 0 20,000 0 101,720
19 Dec 19 Zackary S. Irani Non Qualified Stock Option Common Stock Grant Aquire A 2.81 125,000 351.25K 555,000
19 Dec 19 Jane Emerson Non Qualified Stock Option Common Stock Grant Aquire A 2.81 30,000 84.3K 145,000
2.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 11 11
Opened positions 1 2 -50.0%
Closed positions 1 4 -75.0%
Increased positions 2 2
Reduced positions 1 1
13F shares
Current Prev Q Change
Total value 704K 752K -6.4%
Total shares 235.08K 231.79K +1.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 126.22K $375K 0.0%
Perritt Capital Management 65K $197K 0.0%
Heritage Investors Management 15.55K $47K 0.0%
Bard Associates 10K $30K 0.0%
WFC Wells Fargo & Co. 6.5K $20K 0.0%
BLK BlackRock 5.87K $18K NEW
BAC Bank of America 3.83K $12K 0.0%
Victory Capital Management 1.46K $4K +9.0%
DB Deutsche Bank 590 $1K -74.7%
RY Royal Bank of Canada 50 $0 +212.5%
Largest transactions
Shares Bought/sold Change
BLK BlackRock 5.87K +5.87K NEW
DB Deutsche Bank 590 -1.74K -74.7%
LTS Ladenburg Thalmann Financial Services 0 -1K EXIT
Victory Capital Management 1.46K +121 +9.0%
RY Royal Bank of Canada 50 +34 +212.5%
Heritage Investors Management 15.55K 0 0.0%
WFC Wells Fargo & Co. 6.5K 0 0.0%
Proequities 0 0
Bard Associates 10K 0 0.0%
Perritt Capital Management 65K 0 0.0%

Financial report summary

?
Management Discussion
  •       Consolidated net sales for Biomerica were $1,596,408 for the three months ended November 30, 2019 as compared to $1,500,791 for the same period in the previous year. This represents an increase of $95,617 or 6.4%. For the six-month period ended November 30, 2019 as compared to 2018, net sales were $2,790,823 as compared to $2,773,661.  This represents an increase of $17,162 or 0.6%. The increase for the three and six-month periods was primarily due to increased sales to Asia and several orders to the Middle East. 
  •      For the three months ended November 30, 2019 as compared to November 30, 2018, cost of sales decreased as a percentage of sales from 72.8% of sales, or $1,092,731, to 70.6% of sales, or $1,127,536. For the six months ended November 30, 2019 as compared to 2018, cost of sales decreased as a percentage of sales from 73.1% of sales, or $2,028,378 to 70.0% of sales, or $1,954,647. Decreases to cost of sales as a percentage of sales for the three and six months were due to lower scrap as well as fixed costs in relationship to higher sales.
  •        For the three months ended November 30, 2019 compared to 2018, selling, general and administrative expenses increased by $41,169, or 8.0%. For the six-month period ended November 30, 2019 as compared to 2018, these expenses increased by $148,138, or 16.1%. The increase in the three and six-month period was primarily due to increased wages primarily due to increased wages classified as administrative and the addition of a sales manager in Europe.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: addressable, constant, create, deposit, deposited, disease, earned, East, inflammatory, Middle, Multiple, strategic